Search

Your search keyword '"Gribben, John G."' showing total 1,922 results
Start Over Author "Gribben, John G."
1,922 results on '"Gribben, John G."'

1. Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia

Author

Borek, Weronika E., Nobre, Luis, Pedicona, S. Federico, Campbell, Amy E., Christopher, Josie A., Nawaz, Nazrath, Perkins, David N., Moreno-Cardoso, Pedro, Kelsall, Janet, Ferguson, Harriet R., Patel, Bela, Gallipoli, Paolo, Arruda, Andrea, Ambinder, Alex J., Thompson, Andrew, Williamson, Andrew, Ghiaur, Gabriel, Minden, Mark D., Gribben, John G., Britton, David J., Cutillas, Pedro R., and Dokal, Arran D.

Published
2024
Full Text
View/download PDF

3. B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities

Author

Kluckova, Katarina, Clear, Andrew J, D’Avola, Annalisa, Rassenti, Laura Z, Kipps, Thomas J, Gribben, John G, and Riches, John C

Subjects
Hematology, Lymphoma, Rare Diseases, Cancer, 2.1 Biological and endogenous factors, Aetiology
Abstract

It has been unclear what role metabolism is playing in the pathophysiology of chronic lymphocytic leukemia (CLL). One reason is that the study of CLL metabolism is challenging due to the resting nature of circulating CLL cells. Also, it is not clear if any of the genomic aberrations observed in this disease have any impact on metabolism. Here, we demonstrate that CLL cells in proliferation centers exhibit upregulation of several molecules involved in glycolysis and mitochondrial metabolism. Comparison of CXCR4/CD5 intraclonal cell subpopulations showed that these changes are paralleled by increases in the metabolic activity of the CXCR4lowCD5high fraction that have recently egressed from the lymph nodes. Notably, anti-IgM stimulation of CLL cells recapitulates many of these metabolic alterations, including increased glucose uptake, increased lactate production, induction of glycolytic enzymes, and increased respiratory reserve. Treatment of CLL cells with inhibitors of B-cell receptor (BCR) signaling blocked these anti-IgM-induced changes in vitro, which was mirrored by decreases in hexokinase 2 expression in CLL cells from ibrutinib-treated patients in vivo. Interestingly, several samples from patients with 17p-deletion manifested increased spontaneous aerobic glycolysis in the unstimulated state suggestive of a BCR-independent metabolic phenotype. We conclude that the proliferative fraction of CLL cells found in lymphoid tissues or the peripheral blood of CLL patients exhibit increased metabolic activity when compared with the bulk CLL-cell population. Although this is due to microenvironmental stimulatory signals such as BCR-engagement in most cases, increases in resting metabolic activity can be observed in cases with 17p-deletion.

Published
2022

4. Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).

Author

Rodriguez Cutillas, Pedro, primary, Borek, Weronika E., additional, Christopher, Josie A., additional, Nobre, Luis Veiga, additional, Campbell, Amy, additional, Kelsall, Janet, additional, Pedicona, Federico, additional, Nawaz, Nazrath, additional, Perkins, David N., additional, Cardoso, Pedro Moreno, additional, Arruda, Andrea, additional, Ambinder, Alexander Joseph, additional, Dutta, Sayantanee, additional, Gallipoli, Paolo, additional, Sill, Heinz, additional, Ghiaur, Gabriel, additional, Minden, Mark D., additional, Williamson, Andrew, additional, Gribben, John G., additional, and Dokal, Arran David, additional

Published
2024
Full Text
View/download PDF

5. Growth dynamics in naturally progressing chronic lymphocytic leukaemia

Author

Gruber, Michaela, Bozic, Ivana, Leshchiner, Ignaty, Livitz, Dimitri, Stevenson, Kristen, Rassenti, Laura, Rosebrock, Daniel, Taylor-Weiner, Amaro, Olive, Oriol, Goyetche, Reaha, Fernandes, Stacey M, Sun, Jing, Stewart, Chip, Wong, Alicia, Cibulskis, Carrie, Zhang, Wandi, Reiter, Johannes G, Gerold, Jeffrey M, Gribben, John G, Rai, Kanti R, Keating, Michael J, Brown, Jennifer R, Neuberg, Donna, Kipps, Thomas J, Nowak, Martin A, Getz, Gad, and Wu, Catherine J

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Hematology, Cancer, Genetics, Lymphoma, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Cell Proliferation, Clone Cells, Cohort Studies, Disease Progression, Evolution, Molecular, Female, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Neoplasm Recurrence, Local, Recurrence, Reproducibility of Results, General Science & Technology
Abstract

How the genomic features of a patient's cancer relate to individual disease kinetics remains poorly understood. Here we used the indolent growth dynamics of chronic lymphocytic leukaemia (CLL) to analyse the growth rates and corresponding genomic patterns of leukaemia cells from 107 patients with CLL, spanning decades-long disease courses. We found that CLL commonly demonstrates not only exponential expansion but also logistic growth, which is sigmoidal and reaches a certain steady-state level. Each growth pattern was associated with marked differences in genetic composition, the pace of disease progression and the extent of clonal evolution. In a subset of patients, whose serial samples underwent next-generation sequencing, we found that dynamic changes in the disease course of CLL were shaped by the genetic events that were already present in the early slow-growing stages. Finally, by analysing the growth rates of subclones compared with their parental clones, we quantified the growth advantage conferred by putative CLL drivers in vivo.

Published
2019

6. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Author

Robak, Tadeusz, Burger, Jan A, Tedeschi, Alessandra, Barr, Paul M, Owen, Carolyn, Bairey, Osnat, Hillmen, Peter, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven E, Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A, Moreno, Carol, Gill, Devinder S, Flinn, Ian W, Gribben, John G, Mokatrin, Ahmad, Cheng, Mei, Styles, Lori, James, Danelle F, Kipps, Thomas J, and Ghia, Paolo

Subjects
Humans, Pyrazoles, Pyrimidines, Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Immunotherapy, Survival Analysis, Retrospective Studies, Aged, Middle Aged, Female, Male, Clinical Trials as Topic, Leukemia, Lymphocytic, Chronic, B-Cell, Cancer, Clinical Trials and Supportive Activities, Lymphoma, Rare Diseases, Clinical Research, Hematology, 6.1 Pharmaceuticals, Immunology, Cardiorespiratory Medicine and Haematology
Abstract

Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. Using ibrutinib data from the RESONATE-2 (PCYC-1115/1116) study conducted in patients ≥65 years without del(17p), we performed a cross-trial comparison with CIT data from published phase 3 studies in first-line treatment of CLL. Progression-free survival (PFS), overall survival (OS), and safety data for ibrutinib (median follow-up 35.7 months) were evaluated alongside available CIT data. CIT regimens included: fludarabine + cyclophosphamide + rituximab (CLL8, CLL10), bendamustine + rituximab (CLL10), obinutuzumab + chlorambucil and rituximab + chlorambucil (CLL11), and ofatumumab + chlorambucil (COMPLEMENT-1). Median age across studies was 61-74 years, with older populations receiving ibrutinib, obinutuzumab + chlorambucil, or rituximab + chlorambucil. Median follow-up varied across studies/regimens (range 14.5-37.4 months). Among all patients, PFS appeared longer with ibrutinib relative to CIT and OS appeared comparable. Relative to CIT studies that similarly excluded patients with del(17p) (CLL10) or enrolled older/less-fit patients (CLL11), PFS appeared favorable for ibrutinib in high-risk subgroups, including advanced disease, bulky lymph nodes, unmutated IGHV status, and presence of del(11q). Grade ≥ 3 infections ranged from 9% (ofatumumab + chlorambucil) to 40% (fludarabine + cyclophosphamide + rituximab), and was 25% with ibrutinib. Grade ≥ 3 neutropenia was 12% for ibrutinib and 26%-84% for CIT. Although definitive conclusions cannot be made due to inherent limitations of cross-trial comparisons, this report suggests that ibrutinib has a favorable benefit/risk profile and may potentially eliminate the need for chemotherapy in some patients. Randomized, comparative studies are needed to support these findings.

Published
2018

7. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Author

Campo, Elias, Jaffe, Elaine S., Cook, James R., Quintanilla-Martinez, Leticia, Swerdlow, Steven H., Anderson, Kenneth C., Brousset, Pierre, Cerroni, Lorenzo, de Leval, Laurence, Dirnhofer, Stefan, Dogan, Ahmet, Feldman, Andrew L., Fend, Falko, Friedberg, Jonathan W., Gaulard, Philippe, Ghia, Paolo, Horwitz, Steven M., King, Rebecca L., Salles, Gilles, San-Miguel, Jesus, Seymour, John F., Treon, Steven P., Vose, Julie M., Zucca, Emanuele, Advani, Ranjana, Ansell, Stephen, Au, Wing-Yan, Barrionuevo, Carlos, Bergsagel, Leif, Chan, Wing C., Cohen, Jeffrey I., d'Amore, Francesco, Davies, Andrew, Falini, Brunangelo, Ghobrial, Irene M., Goodlad, John R., Gribben, John G., Hsi, Eric D., Kahl, Brad S., Kim, Won-Seog, Kumar, Shaji, LaCasce, Ann S., Laurent, Camille, Lenz, Georg, Leonard, John P., Link, Michael P., Lopez-Guillermo, Armando, Mateos, Maria Victoria, Macintyre, Elizabeth, Melnick, Ari M., Morschhauser, Franck, Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid, Pileri, Stefano A., Piris, Miguel, Pro, Barbara, Rajkumar, Vincent, Rosen, Steven T., Sander, Birgitta, Sehn, Laurie, Shipp, Margaret A., Smith, Sonali M., Staudt, Louis M., Thieblemont, Catherine, Tousseyn, Thomas, Wilson, Wyndham H., Yoshino, Tadashi, Zinzani, Pier-Luigi, Dreyling, Martin, Scott, David W., Winter, Jane N., and Zelenetz, Andrew D.

Published
2022
Full Text
View/download PDF

11. PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma

Author

D’Avola, Annalisa, primary, Legrave, Nathalie, additional, Tajan, Mylène, additional, Chakravarty, Probir, additional, Shearer, Ryan L., additional, King, Hamish W., additional, Kluckova, Katarina, additional, Cheung, Eric C., additional, Clear, Andrew J., additional, Gunawan, Arief S., additional, Zhang, Lingling, additional, James, Louisa K., additional, MacRae, James I., additional, Gribben, John G., additional, Calado, Dinis P., additional, Vousden, Karen H., additional, and Riches, John C., additional

Published
2024
Full Text
View/download PDF

16. A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma

Author

Ghione, Paola, primary, Palomba, M Lia, additional, Ray, Markqayne D, additional, Limbrick-Oldfield, Eve, additional, Owen, Jessica, additional, Kanters, Steve, additional, Bobillo, Sabela, additional, Ribiero, Maria Teresa, additional, Jacobson, Caron A, additional, Neelapu, Sattva S, additional, Ghesquieres, Herve, additional, Nahas, Myrna, additional, Beygi, Sara, additional, Patel, Anik R, additional, and Gribben, John G, additional

Published
2024
Full Text
View/download PDF

17. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Author

Wendtner, Clemens M, Hallek, Michael, Fraser, Graeme AM, Michallet, Anne-Sophie, Hillmen, Peter, Dürig, Jan, Kalaycio, Matt, Gribben, John G, Stilgenbauer, Stephan, Buhler, Andreas, Kipps, Thomas J, Purse, Brendan, Zhang, Jennie, De Bedout, Sabine, Mei, Jay, and Chanan-Khan, Asher

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Patient Safety, Hematology, Lymphoma, Rare Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Resistance, Neoplasm, Female, Humans, Immunologic Factors, Kaplan-Meier Estimate, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Staging, Recurrence, Retreatment, Thalidomide, Treatment Outcome, Clinical trial, CLL, lenalidomide, phase II, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

The objective of this study was to evaluate the safety and efficacy of different lenalidomide starting doses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). CLL patients were randomized to receive lenalidomide at initial doses of 5, 10, or 15 mg/d (N = 103). Doses were escalated by 5 mg every 28-d up to a maximum of 25 mg/d; dose reductions in up to 5 mg decrements were permitted. The most common grade ≥3 adverse events (AEs) were neutropenia and thrombocytopenia. Ten patients died during therapy (four deaths considered as related to lenalidomide); 12 patients experienced second primary malignancies. The most common cause for treatment discontinuation was AEs. Overall response rates were similar across arms. Progression-free survival and overall survival rates were longer in patients who escalated treatment (to 15 or 20 mg/d) versus those who did not. Lower starting doses allowed subsequent dose escalation of lenalidomide while maintaining an acceptable tolerability profile in patients with relapsed/refractory CLL.

Published
2016

20. Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma

Author

Lazarian, Gregory, Friedrich, Chloe, Quinquenel, Anne, Tran, Julie, Ouriemmi, Souhail, Dondi, Elisabetta, Martin, Antoine, Mihoub, Imane, Chiron, David, Bellanger, Céline, Fleury, Carole, Gélébart, Pascal, McCormack, Emmet, Ledoux, Dominique, Thieblemont, Catherine, Marzec, Jacek, Gribben, John G., Cymbalista, Florence, Varin-Blank, Nadine, Gardano, Laura, and Baran-Marszak, Fanny

Published
2020
Full Text
View/download PDF

21. PHGDH is required for germinal center formation and is a therapeutic target in MYC- driven lymphoma

Author

D'Avola, Annalisa, Legrave, Nathalie, Tajan, Mylene, Chakravarty, Probir, Shearer, Ryan L., King, Hamish W., Kluckova, Katarina, Cheung, Eric C., Clear, Andrew J., Gunawan, Arief S., Zhang, Lingling, James, Louisa K., MacRae, James I., Gribben, John G., Calado, Dinis P., Vousden, Karen H., and Riches, John C.

Subjects
Oncology, Experimental, Lymphomas -- Genetic aspects -- Development and progression -- Care and treatment, Cell metabolism -- Research, Glucose metabolism -- Research, Cancer -- Research, Oxidoreductases -- Genetic aspects -- Physiological aspects, Health care industry
Abstract

The synthesis of serine from glucose is a key metabolic pathway supporting cellular proliferation in healthy and malignant cells. Despite this, the role that this aspect of metabolism plays in germinal center biology and pathology is not known. Here, we performed a comprehensive characterization of the role of the serine synthesis pathway in germinal center B cells and lymphomas derived from these cells. We demonstrate that upregulation of a functional serine synthesis pathway is a metabolic hallmark of B cell activation and the germinal center reaction. Inhibition of phosphoglycerate dehydrogenase (PHGDH), the first and rate-limiting enzyme in this pathway, led to defective germinal formation and impaired high-affinity antibody production. In addition, overexpression of enzymes involved in serine synthesis was a characteristic of germinal center B cell-derived lymphomas, with high levels of expression being predictive of reduced overall survival in diffuse large B cell lymphoma. Inhibition of PHGDH induced apoptosis in lymphoma cells, reducing disease progression. These findings establish PHGDH as a critical player in humoral immunity and a clinically relevant target in lymphoma., Introduction B cells play a critical role in the humoral immune response that eliminates threats to the host by secreting highly specific antibodies. Activated B cells (ABCs) can either differentiate [...]

Published
2022
Full Text
View/download PDF

22. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Author

Rejeski, Kai, primary, Subklewe, Marion, additional, Aljurf, Mahmoud, additional, Bachy, Emmanuel, additional, Balduzzi, Adriana, additional, Barba, Pere, additional, Bruno, Benedetto, additional, Benjamin, Reuben, additional, Carrabba, Matteo G., additional, Chabannon, Christian, additional, Ciceri, Fabio, additional, Corradini, Paolo, additional, Delgado, Julio, additional, Di Blasi, Roberta, additional, Greco, Raffaella, additional, Houot, Roch, additional, Iacoboni, Gloria, additional, Jäger, Ulrich, additional, Kersten, Marie José, additional, Mielke, Stephan, additional, Nagler, Arnon, additional, Onida, Francesco, additional, Peric, Zinaida, additional, Roddie, Claire, additional, Ruggeri, Annalisa, additional, Sánchez-Guijo, Fermín, additional, Sánchez-Ortega, Isabel, additional, Schneidawind, Dominik, additional, Schubert, Maria-Luisa, additional, Snowden, John A., additional, Thieblemont, Catherine, additional, Topp, Max, additional, Zinzani, Pier Luigi, additional, Gribben, John G., additional, Bonini, Chiara, additional, Sureda, Anna, additional, and Yakoub-Agha, Ibrahim, additional

Published
2023
Full Text
View/download PDF

24. S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA

Author

Dokal, Arran, primary, Borek, Weronika E., additional, Nobre, Luis, additional, Federico Pedicona, Salvatore, additional, Wrench, Bela, additional, Gallipoli, Paolo, additional, Arruda, Andrea, additional, Campbell, Amy E., additional, Nawaz, Nazrath, additional, Ferguson, Harriet R., additional, Perkins, David N., additional, Moreno-Cardoso, Pedro, additional, Thompson, Andrew, additional, Williamson, Andrew J.K., additional, Minden, Mark D., additional, Gribben, John G., additional, Britton, David J., additional, and Cutillas, Pedro R., additional

Published
2023
Full Text
View/download PDF

27. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

Author

Townsend, William, primary, Hiddemann, Wolfgang, additional, Buske, Christian, additional, Cartron, Guillaume, additional, Cunningham, David, additional, Dyer, Martin J.S., additional, Gribben, John G., additional, Phillips, Elizabeth H., additional, Dreyling, Martin, additional, Seymour, John F., additional, Grigg, Andrew, additional, Trotman, Judith, additional, Lin, Tong-Yu, additional, Hong, Xiao-Nan, additional, Kingbiel, Dirk, additional, Nielsen, Tina G., additional, Knapp, Andrea, additional, Herold, Michael, additional, and Marcus, Robert, additional

Published
2023
Full Text
View/download PDF

30. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA

Author

Rejeski, Kai, primary, Greco, Raffaella, additional, Onida, Francesco, additional, Sánchez-Ortega, Isabel, additional, Bonini, Chiara, additional, Sureda, Anna, additional, Gribben, John G., additional, Yakoub-Agha, Ibrahim, additional, and Subklewe, Marion, additional

Published
2023
Full Text
View/download PDF

31. Supplemental Information from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients

Author

Griessinger, Emmanuel, primary, Anjos-Afonso, Fernando, primary, Vargaftig, Jacques, primary, Taussig, David C., primary, Lassailly, François, primary, Prebet, Thomas, primary, Imbert, Véronique, primary, Nebout, Marielle, primary, Vey, Norbert, primary, Chabannon, Christian, primary, Filby, Andrew, primary, Bollet-Quivogne, Frederic, primary, Gribben, John G., primary, Peyron, Jean-François, primary, and Bonnet, Dominique, primary

Published
2023
Full Text
View/download PDF

32. Supplemental Table from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients

Author

Griessinger, Emmanuel, primary, Anjos-Afonso, Fernando, primary, Vargaftig, Jacques, primary, Taussig, David C., primary, Lassailly, François, primary, Prebet, Thomas, primary, Imbert, Véronique, primary, Nebout, Marielle, primary, Vey, Norbert, primary, Chabannon, Christian, primary, Filby, Andrew, primary, Bollet-Quivogne, Frederic, primary, Gribben, John G., primary, Peyron, Jean-François, primary, and Bonnet, Dominique, primary

Published
2023
Full Text
View/download PDF

33. Data from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients

Author

Griessinger, Emmanuel, primary, Anjos-Afonso, Fernando, primary, Vargaftig, Jacques, primary, Taussig, David C., primary, Lassailly, François, primary, Prebet, Thomas, primary, Imbert, Véronique, primary, Nebout, Marielle, primary, Vey, Norbert, primary, Chabannon, Christian, primary, Filby, Andrew, primary, Bollet-Quivogne, Frederic, primary, Gribben, John G., primary, Peyron, Jean-François, primary, and Bonnet, Dominique, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies

Author

Coutinho, Rita, primary, Clear, Andrew James, primary, Owen, Andrew, primary, Wilson, Andrew, primary, Matthews, Janet, primary, Lee, Abigail, primary, Alvarez, Rute, primary, da Silva, Maria Gomes, primary, Cabeçadas, José, primary, Calaminici, Maria, primary, and Gribben, John G., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies

Author

Coutinho, Rita, primary, Clear, Andrew James, primary, Owen, Andrew, primary, Wilson, Andrew, primary, Matthews, Janet, primary, Lee, Abigail, primary, Alvarez, Rute, primary, da Silva, Maria Gomes, primary, Cabeçadas, José, primary, Calaminici, Maria, primary, and Gribben, John G., primary

Published
2023
Full Text
View/download PDF

36. Supplemental Figures from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients

Author

Griessinger, Emmanuel, primary, Anjos-Afonso, Fernando, primary, Vargaftig, Jacques, primary, Taussig, David C., primary, Lassailly, François, primary, Prebet, Thomas, primary, Imbert, Véronique, primary, Nebout, Marielle, primary, Vey, Norbert, primary, Chabannon, Christian, primary, Filby, Andrew, primary, Bollet-Quivogne, Frederic, primary, Gribben, John G., primary, Peyron, Jean-François, primary, and Bonnet, Dominique, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure Legend from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies

Author

Coutinho, Rita, primary, Clear, Andrew James, primary, Owen, Andrew, primary, Wilson, Andrew, primary, Matthews, Janet, primary, Lee, Abigail, primary, Alvarez, Rute, primary, da Silva, Maria Gomes, primary, Cabeçadas, José, primary, Calaminici, Maria, primary, and Gribben, John G., primary

Published
2023
Full Text
View/download PDF

38. Lack of reproducibility of histopathological features in MYC ‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium

Author

Natkunam, Yasodha, primary, de Jong, Daphne, additional, Farinha, Pedro, additional, Gaulard, Philippe, additional, Klapper, Wolfram, additional, Rosenwald, Andreas, additional, Sander, Birgitta, additional, Tooze, Reuben, additional, Advani, Ranjana, additional, Burton, Catherine, additional, Gribben, John G, additional, Kersten, Marie‐José, additional, Kimby, Eva, additional, Lenz, Georg, additional, Molina, Thierry, additional, Morschhauser, Franck, additional, Scott, David, additional, Sehn, Laurie, additional, Stevens, Wendy, additional, Clear, Andrew, additional, Baia, Maryse, additional, Habi, Abdelmalek, additional, Elsensohn, Mad‐Helenie, additional, Langlois‐Jacques, Carole, additional, Maucort‐Boulch, Delphine, additional, and Calaminici, Maria, additional

Published
2023
Full Text
View/download PDF

41. Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1 -mutated myelodysplasia

Author

Mian, Syed A., primary, Philippe, Céline, additional, Maniati, Eleni, additional, Protopapa, Pantelitsa, additional, Bergot, Tiffany, additional, Piganeau, Marion, additional, Nemkov, Travis, additional, Di Bella, Doriana, additional, Morales, Valle, additional, Finch, Andrew J., additional, D’Alessandro, Angelo, additional, Bianchi, Katiuscia, additional, Wang, Jun, additional, Gallipoli, Paolo, additional, Kordasti, Shahram, additional, Kubasch, Anne Sophie, additional, Cross, Michael, additional, Platzbecker, Uwe, additional, Wiseman, Daniel H., additional, Bonnet, Dominique, additional, Bernard, Delphine G., additional, Gribben, John G., additional, and Rouault-Pierre, Kevin, additional

Published
2023
Full Text
View/download PDF

42. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Author

Rejeski, K, Subklewe, M, Aljurf, M, Bachy, E, Balduzzi, A, Barba, P, Bruno, B, Benjamin, R, Carrabba, M, Chabannon, C, Ciceri, F, Corradini, P, Delgado, J, Di Blasi, R, Greco, R, Houot, R, Iacoboni, G, Jaeger, U, Kersten, M, Mielke, S, Nagler, A, Onida, F, Peric, Z, Roddie, C, Ruggeri, A, Sanchez-Guijo, F, Sánchez-Ortega, I, Schneidawind, D, Schubert, M, Snowden, J, Thieblemont, C, Topp, M, Zinzani, P, Gribben, J, Bonini, C, Sureda Balari, A, Yakoub-Agha, I, Rejeski, Kai, Subklewe, Marion, Aljurf, Mahmoud, Bachy, Emmanuel, Balduzzi, Adriana Cristina, Barba, Pere, Bruno, Benedetto, Benjamin, Reuben, Carrabba, Matteo Giovanni, Chabannon, Christian, Ciceri, Fabio, Corradini, Paolo, Delgado, Julio, Di Blasi, Roberta, Greco, Raffaella, Houot, Roch, Iacoboni, Gloria, Jaeger, Ulrich, Kersten, Marie José, Mielke, Stephan, Nagler, Arnon, Onida, Francesco, Peric, Zinaida, Roddie, Claire, Ruggeri, Annalisa, Sanchez-Guijo, Fermin M, Sánchez-Ortega, Isabel, Schneidawind, Dominik, Schubert, Maria-Luisa, Snowden, John, Thieblemont, Catherine, Topp, Max S, Zinzani, Pierluigi Luigi, Gribben, John G, Bonini, Chiara, Sureda Balari, Anna, Yakoub-Agha, Ibrahim, Rejeski, K, Subklewe, M, Aljurf, M, Bachy, E, Balduzzi, A, Barba, P, Bruno, B, Benjamin, R, Carrabba, M, Chabannon, C, Ciceri, F, Corradini, P, Delgado, J, Di Blasi, R, Greco, R, Houot, R, Iacoboni, G, Jaeger, U, Kersten, M, Mielke, S, Nagler, A, Onida, F, Peric, Z, Roddie, C, Ruggeri, A, Sanchez-Guijo, F, Sánchez-Ortega, I, Schneidawind, D, Schubert, M, Snowden, J, Thieblemont, C, Topp, M, Zinzani, P, Gribben, J, Bonini, C, Sureda Balari, A, Yakoub-Agha, I, Rejeski, Kai, Subklewe, Marion, Aljurf, Mahmoud, Bachy, Emmanuel, Balduzzi, Adriana Cristina, Barba, Pere, Bruno, Benedetto, Benjamin, Reuben, Carrabba, Matteo Giovanni, Chabannon, Christian, Ciceri, Fabio, Corradini, Paolo, Delgado, Julio, Di Blasi, Roberta, Greco, Raffaella, Houot, Roch, Iacoboni, Gloria, Jaeger, Ulrich, Kersten, Marie José, Mielke, Stephan, Nagler, Arnon, Onida, Francesco, Peric, Zinaida, Roddie, Claire, Ruggeri, Annalisa, Sanchez-Guijo, Fermin M, Sánchez-Ortega, Isabel, Schneidawind, Dominik, Schubert, Maria-Luisa, Snowden, John, Thieblemont, Catherine, Topp, Max S, Zinzani, Pierluigi Luigi, Gribben, John G, Bonini, Chiara, Sureda Balari, Anna, and Yakoub-Agha, Ibrahim

Abstract

Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infectious complications. In a recent worldwide survey, we demonstrated that there remains considerable heterogeneity in regard to current practice patterns. Here, we sought to build consensus on the grading and management of immune effector cell–associated hematotoxicity (ICAHT) after CAR T-cell therapy. For this purpose, a joint effort between the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international panel of 36 CAR T-cell experts who met in a series of virtual conferences, culminating in a 2-day meeting in Lille, France. On the basis of these deliberations, best practice recommendations were developed. For the grading of ICAHT, a classification system based on depth and duration of neutropenia was developed for early (day 0-30) and late (after day +30) cytopenia. Detailed recommendations on risk factors, available preinfusion scoring systems (eg, CAR-HEMATOTOX score), and diagnostic workup are provided. A further section focuses on identifying hemophagocytosis in the context of severe hematotoxicity. Finally, we review current evidence and provide consensus recommendations for the management of ICAHT, including growth factor support, anti-infectious prophylaxis, transfusions, autologous hematopoietic stem cell boost, and allogeneic hematopoietic cell transplantation. In conclusion, we propose ICAHT as a novel toxicity category after immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic workup and short- and long-term management.

Published
2023

43. A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care

Author

El-Galaly, Tarec Christoffer, Gaidzik, Verena I., Gaman, Mihnea Alexandru, Antic, Darko, Okosun, Jessica, Copland, Mhairi, Sexl, Veronika, Fielding, Adele K., Doeswijk, Robin, Parker, Helen, Dreyling, Martin, Döhner, Konstanze, Almeida, António Medina, Macintyre, Elizabeth, Gribben, John G., Grønbæk, Kirsten, El-Galaly, Tarec Christoffer, Gaidzik, Verena I., Gaman, Mihnea Alexandru, Antic, Darko, Okosun, Jessica, Copland, Mhairi, Sexl, Veronika, Fielding, Adele K., Doeswijk, Robin, Parker, Helen, Dreyling, Martin, Döhner, Konstanze, Almeida, António Medina, Macintyre, Elizabeth, Gribben, John G., and Grønbæk, Kirsten

Abstract

Diversity, equity, and inclusion (DEI) in research is important. This is the case not only because it is simply the right thing to do but also because DEI fosters collaboration, empathy, and psychological safety between scientists and clinicians as well as in our attitudes to and relations with patients. Inclusion of patient samples from diverse populations is critical to ensure that the full range of biological variabilities are represented in basic and clinical research.

Published
2023

46. Contributors

Author

Abdel-Wahab, Omar, primary, Abrahm, Janet L., additional, Adams, Sharon, additional, Adewoye, Adeboye H., additional, Allen, Carl, additional, Ambinder, Richard F., additional, Anasetti, Claudio, additional, Anastasi, John, additional, Anderson, Julia A., additional, Antin, Joseph H., additional, Antony, Aśok C., additional, Araten, David J., additional, Armand, Philippe, additional, Armstrong, Gillian, additional, Armstrong, Scott A., additional, Arnold, Donald M., additional, Artz, Andrew S., additional, Awan, Farrukh T., additional, Baglin, Trevor P., additional, Benson, Don M., additional, Benz, Edward J., additional, Berliner, Nancy, additional, Bhagat, Govind, additional, Bhardwaj, Nina, additional, Bhatia, Ravi, additional, Bhatia, Smita, additional, Bhatt, Mihir D., additional, Bhatt, Vijaya Raj, additional, Bitan, Menachem, additional, Blinderman, Craig D., additional, Bollard, Catherine M., additional, Braun, Benjamin S., additional, Brenner, Malcolm K., additional, Brittenham, Gary M., additional, Brodsky, Robert A., additional, Brown, Myles, additional, Broxmeyer, Hal E., additional, Brummel-Ziedins, Kathleen, additional, Brunner, Andrew M., additional, Buadi, Francis K., additional, Burkhardt, Birgit, additional, Burns, Melissa, additional, Byrd, John C., additional, Caimi, Paolo F., additional, Caligiuri, Michael A., additional, Canavan, Michelle, additional, Cantor, Alan B., additional, Carcao, Manuel, additional, Carroll, Michael C., additional, Carty, Shannon A., additional, Castillo, Jorge J., additional, Chan, Anthony K.C., additional, Chapin, John, additional, Chiu, April, additional, Chute, John P., additional, Clark, David B., additional, Coates, Thomas D., additional, Cogle, Christopher R., additional, Connell, Nathan T., additional, Cooke, Elizabeth, additional, Cooley, Sarah, additional, Corradini, Paolo, additional, Creager, Mark A., additional, Creger, Richard J., additional, Cromwell, Caroline, additional, Crowther, Mark A., additional, Cushing, Melissa M., additional, Cutler, Corey, additional, Dang, Chi V., additional, Danial, Nika N., additional, Dave, Sandeep S., additional, DeCaprio, James A., additional, Dinauer, Mary C., additional, Dinner, Shira, additional, Diz-Küçükkaya, Reyhan, additional, Dodd, Roger Y., additional, Donato, Michele L., additional, Dorshkind, Kenneth, additional, Dotti, Gianpietro, additional, Dror, Yigal, additional, Dunleavy, Kieron, additional, Dvorak, Christopher C., additional, Ebert, Benjamin L., additional, Eck, Michael J., additional, Eikelboom, John W., additional, Epperla, Narendranath, additional, Ershler, William B., additional, Evans, William E., additional, Faderl, Stefan, additional, Ferrara, James L.M., additional, Filipovich, Alexandra Hult, additional, Fischer, Martin, additional, Fredenburgh, James C., additional, Friedman, Kenneth D., additional, Fuchs, Ephraim, additional, Fuller, Stephen J., additional, Gailani, David, additional, Galipeau, Jacques, additional, Gallagher, Patrick G., additional, Ganapathi, Karthik A., additional, Gardner, Lawrence B., additional, Gee, Adrian P., additional, Gerson, Stanton L., additional, Gertz, Morie A., additional, Giardina, Patricia J., additional, Gibson, Christopher J., additional, Golan, Karin, additional, Golub, Todd R., additional, Gonzales, Matthew J., additional, Gotlib, Jason, additional, Gottschalk, Stephen, additional, Grant, Marianne A., additional, Graubert, Timothy A., additional, Gregg, Xylina T., additional, Gribben, John G., additional, Gross, Dawn M., additional, Gruber, Tanja A., additional, Guitart, Joan, additional, Gurbuxani, Sandeep, additional, Gur-Cohen, Shiri, additional, Gutierrez, Alejandro, additional, Hamadani, Mehdi, additional, Hari, Parameswaran N., additional, Hartwig, John H., additional, Hayman, Suzanne R., additional, Hayward, Catherine P.M., additional, Hebbel, Robert P., additional, Heslop, Helen E., additional, Hillis, Christopher, additional, Hillyer, Christopher D., additional, Ho, Karin, additional, Hockenbery, David M., additional, Hoffman, Ronald, additional, Hogg, Kerstin E., additional, Holtan, Shernan G., additional, Horny, Hans-Peter, additional, Hsu, Yen-Michael S., additional, Hunter, Zachary R., additional, Huntington, James A., additional, Iancu-Rubin, Camelia, additional, Iqbal, Ali, additional, Isenman, David E., additional, Israels, Sara J., additional, Italiano, Joseph E., additional, Jaffe, Elaine S., additional, Jaffer, Iqbal H., additional, Jagannath, Sundar, additional, Jäger, Ulrich, additional, Jain, Nitin, additional, James, Paula, additional, Jeha, Sima, additional, Jordan, Michael B., additional, Josephson, Cassandra D., additional, Jung, Moonjung, additional, Kager, Leo, additional, Kambayashi, Taku, additional, Kanakry, Jennifer A., additional, Kantarjian, Hagop M., additional, Kaplan, Jason, additional, Karafin, Matthew S., additional, Karsan, Aly, additional, Kaufman, Randal J., additional, Kaufman, Richard M., additional, Keller, Frank G., additional, Kelly, Kara M., additional, Kessler, Craig M., additional, Key, Nigel S., additional, Keyzner, Alla, additional, Khandoga, Alexander G., additional, Khanna-Gupta, Arati, additional, Khatib-Massalha, Eman, additional, Klein, Harvey G., additional, Knoechel, Birgit, additional, Kollet, Orit, additional, Konkle, Barbara A., additional, Kontoyiannis, Dimitrios P., additional, Koreth, John, additional, Koretzky, Gary A., additional, Kotecha, Dipak, additional, Kremyanskaya, Marina, additional, Kumari, Anju, additional, Kuzel, Timothy M., additional, Küppers, Ralf, additional, Lacy, Martha Q., additional, Ladas, Elana, additional, Landier, Wendy, additional, Lapid, Kfir, additional, Lapidot, Tsvee, additional, Larson, Peter J., additional, Levi, Marcel, additional, Lewis, Russell E., additional, Liebman, Howard A., additional, Lillicrap, David, additional, Lim, Wendy, additional, Lin, Judith C., additional, Lindblad, Robert, additional, Lip, Gregory Y.H., additional, Little, Jane A., additional, Lohr, Jens G., additional, López, José A., additional, Luscinskas, Francis W., additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneet S., additional, Manches, Olivier, additional, Mandle, Robert J., additional, Mann, Kenneth G., additional, Manno, Catherine S., additional, Marcogliese, Andrea N., additional, Mariani, Guglielmo, additional, Marincola, Francesco M., additional, Mascarenhas, John, additional, Massberg, Steffen, additional, McEver, Rodger P., additional, McGrath, Emer, additional, McKinney, Matthew S., additional, Mehta, Rohtesh S., additional, Mentzer, William C., additional, Merlini, Giampaolo, additional, Merryman, Reid, additional, Michel, Marc, additional, Migliaccio, Anna Rita, additional, Miller, Jeffrey S., additional, Mims, Martha P., additional, Mondoro, Traci Heath, additional, Moorehead, Paul, additional, Muniz, Luciana R., additional, Munshi, Nikhil C., additional, Najfeld, Vesna, additional, Nayak, Lalitha, additional, Nazy, Ishac, additional, Neff, Anne T., additional, Ness, Paul M., additional, Notarangelo, Luigi D., additional, O'Brien, Sarah H., additional, O'Connor, Owen A., additional, O'Donnell, Martin, additional, Olson, Amanda, additional, Orkin, Stuart H., additional, Pai, Menaka, additional, Pai, Sung-Yun, additional, Paidas, Michael, additional, Panch, Sandhya R., additional, Pande, Reena L., additional, Papayannopoulou, Thalia, additional, Parikh, Rahul, additional, Petersdorf, Effie W., additional, Peterson, Shane E., additional, Pittaluga, Stefania, additional, Ponce, Doris M., additional, Popolo, Laura, additional, Prchal, Josef T., additional, Pui, Ching-Hon, additional, Puigserver, Pere, additional, Rak, Janusz, additional, Ramos, Carlos A., additional, Rand, Jacob H., additional, Rand, Margaret L., additional, Rao, Dinesh S., additional, Ravandi, Farhad, additional, Rawlings, David J., additional, Reddy, Pavan, additional, Reding, Mark T., additional, Reiter, Andreas, additional, Rice, Lawrence, additional, Riese, Matthew J., additional, Ritchey, Arthur Kim, additional, Roberts, David J., additional, Roman, Elizabeth, additional, Rooney, Cliona M., additional, Rosen, Steven T., additional, Rosenthal, David S., additional, Rossmann, Marlies P., additional, Rot, Antal, additional, Rowley, Scott D., additional, Rubnitz, Jeffrey E., additional, Rydz, Natalia, additional, Salama, Mohamed E., additional, Sauk, Steven, additional, Saunthararajah, Yogen, additional, Savage, William, additional, Scadden, David, additional, Schaefer, Kristen G., additional, Schiffman, Fred, additional, Schneidewend, Robert, additional, Schrier, Stanley L., additional, Schuchman, Edward H., additional, Scullion, Bridget Fowler, additional, Selvaggi, Kathy J., additional, Senoo, Keitaro, additional, Shaheen, Montaser, additional, Shaz, Beth H., additional, Shelburne, Samuel A., additional, Shpall, Elizabeth J., additional, Shurin, Susan B., additional, Siegal, Deborah, additional, Silberstein, Leslie E., additional, Silberstein, Lev, additional, Silverstein, Roy L., additional, Sloan, Steven R., additional, Smith, Franklin O., additional, Smith, James W., additional, Smith, Katy, additional, Steensma, David P., additional, Steinberg, Martin H., additional, Stock, Wendy, additional, Storry, Jill R., additional, Stramer, Susan L., additional, Strauss, Ronald G., additional, Stroncek, David F., additional, Taylor, Justin, additional, Thota, Swapna, additional, Treon, Steven P., additional, Tulpule, Anil, additional, Valdes, Roberto Ferro, additional, Valent, Peter, additional, Vedantham, Suresh, additional, Vercellotti, Gregory M., additional, Verneris, Michael R., additional, Vichinsky, Elliott P., additional, von Andrian, Ulrich H., additional, Vose, Julie M., additional, Wagner, Andrew J., additional, Wang, Ena, additional, Wang, Jia-huai, additional, Warkentin, Theodore E., additional, Wasserstein, Melissa P., additional, Webster, Ann, additional, Weisdorf, Daniel J., additional, Weitz, Jeffrey I., additional, Westhoff, Connie M., additional, Wheeler, Allison P., additional, Widick, Page, additional, Wiley, James S., additional, William, Basem M., additional, Williams, David A., additional, Wilson, Wyndham H., additional, Wolfe, Joanne, additional, Wolgast, Lucia R., additional, Wood, Deborah, additional, Wu, Jennifer, additional, Yahalom, Joachim, additional, Yee, Donald L., additional, Younes, Anas, additional, Young, Neal S., additional, and Zeller, Michelle P., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results